rPFS and cPFS May Act as Surrogate OS End Points in Phase 3

Radiographic and clinical progression-free survival may be surrogates for overall survival in hormone-sensitive prostate cancer clinical trials.

Related Keywords

North Carolina , United States , Jamesb Duke , Susan Halabi , Duke Cancer Institute In Durham , Division Of Biostatistics , Distinguished Professor , Duke Cancer Institute , Surrogacy Analysis , Journal Of Clinical Oncology , Phd , Progression Free Survival , Overall Survival , Hormone Sensitive Prostate Cancer , Clinical Trials , Surrogates , Rpfs And Cpfs Are Surrogates For Os , Rpfs , Cpfs , Phase 3 Clinical Trials , Testosterone Suppression Based Treatment Strategies ,